参考文献/References:
[1] JIN H,LI L,YU W,et al.The efficacy of acupuncture and moxibustion for early and middle-stage osteonecrosis of the femeral head:a systematic review and meta-analysis of randomized controlled trials[J].Medicine(Baltimore),2021,100(22):e26210.
[2] HOPKINS C,GENANT H K.Editorial for guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults(2019 version)[J].J Orthop Translat,2020,21:A1.
[3] ATILLA B,BAKIRCIOGLU S,SHOPE A J,et al.Joint-preserving procedures for osteonecrosis of the femoral head[J].EFORT Open Rev,2020,4(12):647-658.
[4] HATANAKA H,MOTOMURA G,IKEMURA S,et al.Volume of hip synovitis detected on contrast-enhanced magnetic resonance imaging is associated with disease severity after collapse in osteonecrosis of the femoral head[J].Skeletal Radiol,2019,48(8):1193-1200.
[5] RABQUER B J,TAN G J,SHAHEEN P J,et al.Synovial inflammation in patients with osteonecrosis of the femoral head[J].Clin Transl Sci,2009,2(4):273-278.
[6] KORNICKA-GARBOWSKA K,GROBORZ S,LYNDA B,et al.Mitochondria transfer restores fibroblasts-like synoviocytes(FLS)plasticity in LPS-induced,in vitro synovitis model[J].Cell Commun Signal,2022,20(1):137.
[7] CRUZ-TOPETE D,CIDLOWSKI J A.One hormone,two actions:anti-andpro-inflammatory effects of glucocorticoids[J].Neuroimmunomodulation,2015,22(1/2):20-32.
[8] HMAMOUCHI I,PARUK F,TABRA S,et al.Prevalence of glucocorticoid-induced osteoporosis among rheumatology patients in Africa:a systematic review and meta-analysis[J].Arch Osteoporos,2023,18(1):59.
[9] PAVELKA K.Osteonecrosis[J].Baillieres best pract res clin rheumatol,2000,14(2):399-414.
[10] YOON B H,JONES L C,CHEN C H,et al.Etiologic classification criteria of arco on femoral head osteonecrosis part 1:glucocorticoid-associated osteonecrosis[J].J Arthroplasty,2019,34(1):163-168.
[11] MONT M A,ZYWIEL M G,MARKER D R,et al.The natural history of untreated asymptomatic osteonecrosis of the femoral head:a systematic literature review[J].J Bone Joint Surg Am,2010,92(12):2165-2170.
[12] PAP T,DANKBAR B,WEHMEYER C,et al.Synovial fibroblasts and articular tissue remodelling:role and mecha-nisms[J].Semin Cell Dev Biol,2020,101:140-145.
[13] DE LANGE-BROKAAR B J,IOAN-FACSINAY A,VAN OSCH G J,et al.Synovial inflammation,immune cells and their cytokines in osteoarthritis:a review[J].Osteoarthritis Cartilage,2012,20(12):1484-1499.
[14] PENG Y,ZHANG M,HU J.Non-coding RNAs involved in fibroblast-like synoviocyte functioning in arthritis rheumatoid:from pathogenesis to therapy[J].Cytokine,2024,173:156418.
[15] OKAZAKI S,NISHITANI Y,NAGOYA S,et al.Femoral head osteonecrosis can be caused by disruption of the systemic immune response via the Toll-like receptor 4 signalling pathway[J].Rheumatology(Oxford),2009,48(3):227-232.
[16] THOMPSON C D,MATTA B,BARNES B J.therapeutic targeting of IRFs:pathway-dependence or structure-based?[J].Front Immunol,2018,9:2622.
[17] DURBIN R K,KOTENKO S V,DURBIN J E.Interferon induction and function at the mucosal surface[J].Immunol Rev,2013,255(1):25-39.
[18] HE C,ZHENG S,LUO Y,et al.Exosome theranostics:biology and translational medicine[J].Theranostics,2018,8(1):237-255.
[19] NOONIN C,THONGBOONKERD V.Exosome-inflammasome crosstalk and their roles in inflammatory responses[J].Theranostics,2021,11(9):4436-4451.
[20] JEFFERIES C A.Regulating IRFs in IFN driven disease[J].Front Immunol,2019,10:325.
[21] TAMURA T,YANAI H,SAVITSKY D,et al.The IRF family transcription factors in immunity and oncogenesis[J].Annu Rev Immunol,2008,26:535-584.
[22] LOHOFF M,MAK T W.Roles of interferon-regulatory factors in T-helper-cell differentiation[J].Nat Rev Immunol,2005,5(2):125-135.
[23] CHUNG Y,CHANG S H,MARTINEZ G J,et al.Critical regulation of early Th17 cell differentiation by interleukin-1 signaling[J].Immunity,2009,30(4):576-587.
[24] SHARMA S,TENOEVER B R,GRANDVAUX N,et al.Triggering the interferon antiviral response through an IKK-related pathway[J].Science,2003,300(5622):1148-1151.
[25] HONDA K,YANAI H,NEGISHI H,et al.IRF-7 is the master regulator of type-I interferon-dependent immune responses[J].Nature,2005,434(7034):772-777.
[26] VAN BON L,COSSU M,RADSTAKE T R.An update on an immune system that goes awry in systemic sclerosis[J].Curr Opin Rheumatol,2011,23(6):505-510.
[27] SIMONS K H,DE VRIES M R,DE JONG R C M,et al.IRF3 and IRF7 mediate neovascularization via inflammatory cytokines[J].J Cell Mol Med,2019,23(6):3888-3896.
[28] TATEDA K,OKAZAKI S,NAGOYA S,et al.The suppression of TRIM21 and the accumulation of IFN-α play crucial roles in the pathogenesis of osteonecrosis of the femoral head[J].Lab Invest,2012,92(9):1318-1329.
相似文献/References:
[1]陈雷雷,张颖.何伟教授采用中医药疗法治疗股骨头坏死的经验[J].中医正骨,2015,27(10):74.
[2]徐西林,赵永兰,张晓峰,等.活骨注射液髋关节腔灌注对兔股骨头坏死模型
血管内皮生长因子表达的动态影响[J].中医正骨,2015,27(08):1.
XU Xilin,ZHAO Yonglan,ZHANG Xiaofeng,et al.Dynamic effect of intra-articular hip injection of Huogu injection on the expression of vascular endothelial growth factor in rabbit models with femur head necrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(09):1.
[3]周勇,任菲菲,丰凡翔,等.血管内皮生长因子和骨形态发生蛋白2
在非创伤性股骨头坏死不同区域的表达[J].中医正骨,2015,27(08):7.
ZHOU Yong,REN Feifei,FENG Fanxiang,et al.Expressions of vascular endothelial growth factor and bone morphogenetic protein 2 in different zones of femoral head with non-traumatic osteonecrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(09):7.
[4]鲍荣华,王国平,夏晓斌,等.钽棒植入治疗非创伤性股骨头坏死的疗效观察[J].中医正骨,2015,27(02):28.
[5]张兵,马凰富,刘波,等.非创伤性股骨头坏死的舌象定量研究[J].中医正骨,2015,27(04):8.
ZHANG Bing,MA Huangfu,LIU Bo,et al.Quantitative study on tongue manifestation of patients with nontraumatic osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(09):8.
[6]李刚,程春生.股骨头坏死血瘀证症状与平乐郭氏正骨方药药物组成
最大频繁关联模式挖掘[J].中医正骨,2015,27(04):21.
LI Gang,CHENG Chunsheng.Maximal frequent association pattern mining for studying the relationship between BLOOD STASIS syndrome in patients with osteonecrosis of femoral head and drug components of Pingle Guo's orthopedics prescription[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(09):21.
[7]李文龙,梅沉成,杜贵强,等.微创减压植骨多孔钽棒植入治疗
ARCOⅡ期非创伤性缺血性股骨头坏死[J].中医正骨,2016,28(02):43.
[8]张磊,金红婷,童培建.骨健口服液早期干预非创伤性股骨头坏死的临床研究[J].中医正骨,2016,28(03):14.
ZHANG Lei,JIN Hongting,TONG Peijian.Clinical study on Gujian Koufuye(骨健口服液)for early intervention of nontraumatic osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(09):14.
[9]鲍荣华,王国平,夏晓斌,等.直接前入路微创全髋关节置换术治疗晚期股骨头坏死[J].中医正骨,2016,28(03):61.
[10]张超,姚晨,沈计荣.微创髓芯减压打压支撑植骨术结合补肾活血汤口服治疗ARCOⅡ、Ⅲ期股骨头坏死的近期疗效观察[J].中医正骨,2016,28(03):20.
ZHANG Chao,YAO Chen,SHEN Jirong.[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(09):20.
[11]周占国,郭浩山,关涛,等.股骨头坏死病因的相关因素分析[J].中医正骨,2020,32(01):7.
[12]杨琪,杜炯,孙继高,等.股骨头坏死中医证型分析[J].中医正骨,2020,32(01):14.
[13]许珂,宇文星,宋梦歌,等.股骨头坏死全髋关节置换术患者的人群特征与临床特点分析[J].中医正骨,2020,32(01):51.
[14]李向洲,邢涛,张应拴,等.中药治疗激素性股骨头坏死作用机制的研究进展[J].中医正骨,2023,35(02):33.
[15]杨博,邢涛,张应拴,等.从伏邪理论论治激素性股骨头坏死[J].中医正骨,2023,35(02):54.
[16]田佳庆,刘良燕,彭鹏,等.基于“成骨-成血管”理论探讨全身振动疗法治疗激素性股骨头坏死的效果及作用机制[J].中医正骨,2024,36(09):59.
TIAN Jiaqing,LIU Liangyan,PENG Peng,et al.Efficacy and mechanism of whole body vibration therapy in treatment of steroid-induced osteonecrosis of the femoral head:a osteogenesis-angiogenesis theory-based experimental study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2024,36(09):59.
[17]彭鹏,肖欢,方伟华,等.激素性股骨头坏死囊性变组织骨修复机制分析与活血通络胶囊含药血清对肥大软骨细胞成骨分化影响的实验研究[J].中医正骨,2024,36(09):19.
PENG Peng,XIAO Huan,FANG Weihua,et al.[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2024,36(09):19.